This new mRNA vaccine could better protect against the flu - Sudbury News

The U. S.-approved vaccine — faster to produce and more precise than traditional flu shots — is awaiting the green light in Canada Reprinted with permission from Be Giant, a non-profit, non-partisan media outlet reporting on the people, places, ideas and breakthroughs shaping Canada's future. Sign up for their weekly newsletter.

The U. S.-approved vaccine — faster to produce and more precise than traditional flu shots — is awaiting the green light in Canada Reprinted with permission from Be Giant, a non-profit, non-partisan media outlet reporting on the people, places, ideas and breakthroughs shaping Canada's future. Sign up for their weekly newsletter.

Bioengineer.org news storyFor people living with HIV, modern antiretroviral therapy can suppress the virus to levels below what standard laboratory tests can detect. Yet some patients on long-term treatment experience a curious phenomenon: a single test result showing a small, transient amount of virus in the blood, followed by an immediate return to undetectable levels. These events, known as viral blips, have puzzled clinicians and researchers for years, raising questions about whether they represent harmless statistical noise, brief bursts of viral production from hidden reservoirs, or early warnings of impending treatment failure. A new nationwide Swedish study, published in BMC Infectious Diseases, offers one of the most comprehensive answers to date. Drawing on the Swedish national InfCareHIV cohort, researchers analyzed data from 4,210 treatment-naïve adults who began antiretroviral therapy from 1 January 2007 onward, with follow-up data extracted through 30 September 2020. The median observation time was 5.5 years, with some individuals followed for as long as 13.7 years.